Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Hepatocellular Carcinoma (HCC) 1Acrocephalosyndactylia 1

Interventions

Oxaliplatin 3Irinotecan 3Surveys and Questionnaires 2Specimen Handling 2Radiosurgery 2Leucovorin 2Ketamine 2Hydroxychloroquine 2Fluorouracil 2Capecitabine 2ulixertinib 1tegafur-gimeracil-oteracil 1regorafenib 1pazopanib 1lanreotide 1fludarabine phosphate 1fludarabine 1dostarlimab 1dolasetron 1dexamethasone acetate 1dexamethasone 21-phosphate 1danvatirsen 1cobimetinib 1brivanib 1auricularum 1atezolizumab 1alectinib 1aldesleukin 1abelacimab 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Neoplasms × brivanib × Clear all
NCT00300027 2010-03-02

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

Bristol-Myers Squibb

Phase 1 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡